LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

19.75 -1.3

Resumen

Variación precio

24h

Actual

Mínimo

19.65

Máximo

20.09

Métricas clave

By Trading Economics

Ingresos

-4.6M

52M

Ventas

5.1M

147M

P/B

Media del Sector

12.17

35.664

Margen de beneficios

35.553

Empleados

181

EBITDA

5.9M

79M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+65.25% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-167M

2.5B

Apertura anterior

21.05

Cierre anterior

19.75

Noticias sobre sentimiento de mercado

By Acuity

61%

39%

310 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 sept 2025, 22:41 UTC

Principales Movimientos del Mercado

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sept 2025, 16:04 UTC

Principales Movimientos del Mercado

Upexi Shares Climb on Solana Gains

14 sept 2025, 23:48 UTC

Charlas de Mercado

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14 sept 2025, 23:41 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

14 sept 2025, 23:38 UTC

Charlas de Mercado

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14 sept 2025, 23:13 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 sept 2025, 23:04 UTC

Charlas de Mercado

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13 sept 2025, 08:20 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

12 sept 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

12 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 sept 2025, 20:09 UTC

Ganancias

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sept 2025, 19:23 UTC

Charlas de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept 2025, 19:16 UTC

Charlas de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sept 2025, 19:03 UTC

Charlas de Mercado

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sept 2025, 18:59 UTC

Charlas de Mercado

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sept 2025, 18:38 UTC

Charlas de Mercado
Ganancias

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sept 2025, 18:33 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sept 2025, 18:22 UTC

Charlas de Mercado

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sept 2025, 16:56 UTC

Charlas de Mercado

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sept 2025, 16:22 UTC

Ganancias

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sept 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

12 sept 2025, 16:19 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sept 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

12 sept 2025, 16:11 UTC

Ganancias

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sept 2025, 15:37 UTC

Charlas de Mercado

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sept 2025, 15:22 UTC

Charlas de Mercado

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sept 2025, 15:07 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

65.25% repunte

Estimación a 12 Meses

Media 33 USD  65.25%

Máximo 35 USD

Mínimo 31 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

310 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
help-icon Live chat